Department of Neurology, Erzincan Military Hospital, Erzincan, Turkey.
Department of Neurology, Gülhane Military Medical Academy, Ankara, Turkey.
Balkan Med J. 2012 Jun;29(2):184-7. doi: 10.5152/balkanmedj.2012.003. Epub 2012 Jun 1.
Botulinum toxin type-A (BoNTA) has been considered a treatment option for CH. The aim of this study was to assess the effectiveness of BoNTA treatment in patients with medically resistant CH.
Forty patients with CH were included in the study. Patients in the BoNTA group (n=20) were administered 10 U of BoNTA bilaterally to the frontal muscles, 20 U to the temporal muscles, 15 U to the semispinalis capitis, 15 U to the splenius capitis, and 15 U to the trapezius muscles (total: 150 U). Patients in the placebo group (n=20) received 0.2 mL of saline administrated to the same sites. All participations were evaluated 6 and 12 weeks after treatment; side effects, the number of painful days, severity (by visual analogue scale, VAS) and frequency of pain were evaluated.
In the BoNTA group, the severity and frequency of pain 6 and 12 weeks post treatment were significantly lower than pre-treatment levels (p<0.05). At 12 weeks post treatment, the severity and frequency of pain in the BoNTA group were lower than in the placebo group (p<0.05).
The findings suggest that BoNTA was an effective treatment for CH.
肉毒毒素 A 型（BoNTA）已被认为是 CH 的治疗选择。本研究旨在评估 BoNTA 治疗对药物抵抗性 CH 患者的有效性。
40 例 CH 患者纳入本研究。BoNTA 组（n=20）患者双侧额肌注射 10 U BoNTA，颞肌注射 20 U，头半棘肌注射 15 U，头夹肌注射 15 U，斜方肌注射 15 U（总量：150 U）。安慰剂组（n=20）患者接受相同部位注射 0.2 mL 生理盐水。所有参与者在治疗后 6 周和 12 周进行评估；评估副作用、疼痛天数、严重程度（视觉模拟评分，VAS）和疼痛频率。
BoNTA 组治疗后 6 周和 12 周时疼痛的严重程度和频率明显低于治疗前水平（p<0.05）。治疗后 12 周时，BoNTA 组疼痛的严重程度和频率低于安慰剂组（p<0.05）。
这些发现表明 BoNTA 是治疗 CH 的有效方法。
